article thumbnail

Competition is on the horizon for costly narcolepsy treatments

pharmaphorum

But increased competition is on the horizon. Avadel Pharmaceuticals developed Lumryz, a sodium oxybate that is a once-daily, extended-release oral suspension that gained tentative FDA approval in July 2022. Competition starts to heat up. Classic treatment options. Xyrem is one of three that has a patent. About the author.

article thumbnail

Biosimilar competition saves US healthcare $21 billion

European Pharmaceutical Review

Amgen’s 2022 market report has detailed how competition has driven savings across healthcare, estimating that a considerable number of biologics will be in competition with biosimilars in five to 10 years. A rise in savings per quarter was recognised in this year’s data.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FTC order could ease biopharma competition

European Pharmaceutical Review

to address the potential competitive harm Amgen’s $27.8 Consolidation in the pharmaceutical industry has given companies the power and incentive to engage in exclusionary rebating practices, which can lead to sky-rocketing prices on essential medications,” stated Henry Liu, Director of the FTC’s Bureau of Competition.

article thumbnail

ESMO 2022: shrinking market for Trodelvy, with fierce ADC competition

Pharmaceutical Technology

Findings of the study, reported at the ESMO Congress 2022, demonstrated a 3.2-month In addition to Enhertu, Trodelvy may also experience competition from Daiichi/AstraZeneca’s anti-TROP2 ADC, datopotamab deruxtecan (dato-DXd), which is being investigated in the Phase III TROPION-Breast01 trial for previously treated HR+/HER2- patients.

article thumbnail

2022 spells change for EU pharmaceutical legislation

European Pharmaceutical Review

2022 is probably the biggest year in EU pharmaceutical law that I have seen in 30 years. 2022 is undeniably a critical year for change in the pharmaceutical industry: for the first time in several decades, the European Union (EU)’s pharmaceutical legislation is up for review. Key areas of potential legislative change. Future outlook.

article thumbnail

UK life science competitiveness indicators 2022: measuring what matters most?

pharmaphorum

The latest life science competitiveness indicators (LSCIs) were published by the Office of Life Sciences (OLS) in July 2022. The 2022 LSCIs don’t, however, include the speed and volume of NICE Technology Appraisals that were in previous iterations. The July 2022 LSCIs are the eighth version. The life sciences ecosystem.

article thumbnail

Trends in biopharma contract manufacturing 2022

European Pharmaceutical Review

However, China and India are set to be fierce competition over the next decade, with 30 percent of respondents suggesting they would offshore >50 percent of clinical trials and operations to India, China or other lower-cost countries over the next five years.